Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Enterprise Value (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Enterprise Value for 6 consecutive years, with -$78.7 million as the latest value for Q3 2024.

  • On a quarterly basis, Enterprise Value rose 5.2% to -$78.7 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$78.7 million, a 5.2% increase, with the full-year FY2023 number at -$76.7 million, up 29.85% from a year prior.
  • Enterprise Value was -$78.7 million for Q3 2024 at Actinium Pharmaceuticals, up from -$86.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$72.3 million in Q1 2021 to a low of -$116.7 million in Q2 2022.
  • A 4-year average of -$88.0 million and a median of -$83.0 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: plummeted 41.65% in 2022, then increased 29.85% in 2023.
  • Actinium Pharmaceuticals' Enterprise Value stood at -$78.2 million in 2021, then crashed by 39.74% to -$109.3 million in 2022, then rose by 29.85% to -$76.7 million in 2023, then dropped by 2.59% to -$78.7 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Enterprise Value are -$78.7 million (Q3 2024), -$86.0 million (Q2 2024), and -$84.1 million (Q1 2024).